Table 2.
Therapies received in the phase I clinical trials program.
| Phase I therapy | No. of patients | Evaluable (n) | CR (n) | PR (n) | SD≥6mo (n) | SD≥6mo/PR/CR n (%) | Median PFS mo (95%CI) |
|---|---|---|---|---|---|---|---|
| Chemotherapy alonea | 8(8) | 7 | 0 | 0 | 0 | 0/7 (0) | 2.1 (0.9-3.3)c |
| Chemotherapy and targeted agentb | 63 (59) | 57 | 1 | 6 | 4 | 11/57 (19) | 3.0 (1.9-4.1)c |
| Single agent targeted drug | 15(14) | 15 | 0 | 0 | 0 | 0/15 (0) | 1.1 (0.7-1.4)c |
| ≥2 targeted agents | 20 (19) | 19 | 0 | 1 | 0 | 1/19 (5) | 1.9 (1.4-2.4)c |
| Total | 106 (100) | 98 | 1 | 7 | 4 | 12/98 (12) | 2.1 (1.5-2.6) |
a
one or more agents
b
one or more of each
c
p value <0.0001for comparison of PFS by log rank test across all 4 groups
Abbreviations: CR, complete response; CI, confidence interval; mo, months; PR, partial response; PFS, progression-free survival; SD, stable disease